VIRGINIA KAKLAMANI (@VKaklamani) ranks #15 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 13 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: lidERA. CMS Open Payments lists $89,929 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Breast Cancer: US #15 · 13 physicians engaged
- CMS Open Payments lists $89,929 in 2025 general payments.
This Month
What VIRGINIA KAKLAMANI has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies VIRGINIA KAKLAMANI
Physicians who reposted VIRGINIA KAKLAMANI’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #15 | — | 13 | 14 | Full ranking |
What Colleagues Are Saying About VIRGINIA KAKLAMANI
2026 posts by fellow physicians that mention @VKaklamani, quoted word for word.
Leave it to @chadinabhan to pull together an exceptional group of faculty on Monday night at #ASCO26! Looking fwd to joining @DrRanaMcKay & @PGrivasMDPhD to discuss the latest developments in GU oncology - then, @VKaklamani, @stolaney1, #GregVidalMD & #JoyceOShaughnessyMD talk #breastcancer. Terrific faculty for GI, #lungcancer, #melanoma, & #braintumors as well - @DrSapnaPatel, @VivekSubbiah, @YJanjigianMD, @GIcancerDoc & so many more! Join us!
Trials VIRGINIA KAKLAMANI Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| lidERA | 1 | #18 of 23 | Oct 1, 2026 |
VIRGINIA KAKLAMANI on lidERA
Great trial with great results. Compares doublet to doublet and proves that in esr1m tumors addition of giredestrant improves outcomes. These results together with lidera are practice changing. Congrats to all investigators. https://t.co/v8TGcF5XqH
VIRGINIA KAKLAMANI’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
My #esmo26 breast summary: atirmo great data await phase 3; datodxd active in cns; pembro active in pdl1 >10 er+; Chinese “me too” need h2h; same payload no benefit; add tucatinib to delay cns progression; adj cdk os benefit (attn to stats) but giredestrant better tolerability.
Best part of any meeting is the post meeting discussion is data while enjoying the local cuisine @hmcarthur @KateIdaLathrop #esmo2026 https://t.co/MVykIsuio9
Please consider registering during #asco26. Amazing faculty @drsarahsam @curijoey https://t.co/TDPVpVIOHc
Looking forward to an amazing #ESMO26 @KateIdaLathrop @mayscancer https://t.co/fNqEfgVjBx
My kind of town Chicago is…..@KateIdaLathrop #asco2026 @mayscancer https://t.co/klGumgIFnJ
Industry Payments
CMS Open Payments · 2025 general payments
$89,929 across 70 payments